https://www.selleckchem.com/pr....oducts/mpp-iodide.ht
7% (95% confidence interval [CI] 21.6-52.. In stage II, three (12.5%) and 18 (75.0%) of 24 patients had partial response and stable disease, respectively, leading to a DCR of 87.5% (95% CI 67.6-97.3). For 24 patients enrolled in stage II, the median progression-free survival was 5.6 (95% CI 4.1-7.1) months and the overall survival was 14.0 (95% CI 10.7-17.4) months. Treatment-related adverse events occurred in 25% of the patients in stage II, but all were of grade 1 or2. Combination of bevacizumab plus atezolizumab for patients wit